-
About Me
Alison Bass is a Pulitzer Prize nominee and author of Side Effects: A Prosecutor, a Whistleblower and a Bestselling Antidepressant on Trial, which won the NASW Science in Society Award. She was a longtime medical and science writer for The Boston Globe and has also written for The Miami Herald, Psychology Today and MIT's Technology Review, among other publications. A series she wrote for The Boston Globe on psychiatry was nominated for a Pulitzer Prize and she has received many other journalism awards. In 2007, she won a prestigious Alicia Patterson Fellowship to write Side Effects. Bass teaches journalism at Mount Holyoke College and Brandeis University.
Tag Archives: pharmaceutical industry
A review of two new books that attack the DSM-5, psychiatry’s “bible”
Share I reviewed two books now circulating about the DSM and the current controversy over the DSM-5 for The American Scholar — see review here. The two books are The Book of Woe: The DSM and the Unmaking of Psychiatry by … Continue reading
Posted in antidepressants, antipsychotic drugs, conflicts of interest, drug marketing, FDA, pharmaceutical industry, prescription drug abuse, scientific misconduct
Tagged Allen Frances, APA, DSM, DSM-5, Gary Greenberg, NIMH, pharmaceutical industry, prescription drugs, pychiatric diagnoses
Leave a comment
Fast-moving bill in Congress would weaken FDA oversight of new drugs and devices
Share Congress is moving quickly to pass a bill that would authorize higher industry fees for the FDA in exchange for speeding up the approval of some drugs and medical devices and eliminating restrictions on financial conflicts of interest among … Continue reading
How drug companies continue to hide the true story of Tamiflu and other drugs from the American public
Share I’ve been reading Dr. David Healy’s new book, Pharmageddon, and while some of it may seem like old news, I was struck by his fresh analysis of how the pharmaceutical industry has turned the original purpose of clinical trials … Continue reading
From the Pentagon Papers to Allen Jones: Why it’s so hard to be a whistleblower
Share Allen Jones, the whistleblower in an ongoing landmark trial against the pharmaceutical giant Johnson & Johnson, was very much on my mind this past weekend. I was participating in a workshop to develop curriculum to teach college students about … Continue reading
Drug and medical device industry launches push to weaken FDA oversight
Share With the Obama administration hobbled by a Republican-led Congress, the pharmaceutical and medical device industry seems to have launched a concerted push to roll back regulatory initiatives designed to protect consumers from unproven or unsafe drugs and medical devices. … Continue reading